Potential new treatment for kidney failure in cancer patients

April 25, 2017

Kidney dysfunction is a frequent complication affecting more than 50 percent of all cancer patients, and is directly linked to poor survival. Despite the high occurrence, it is still not clear how presence of a tumour contributes to kidney dysfunction and how this can be prevented. A new study from researchers at Uppsala University shows that kidney dysfunction can be caused by the patient's own immune system, 'tricked' by the tumour to become activated.

The study is published in the scientific journal Oncoimmunology and describes how a cell type in the blood, the neutrophil, causes kidney dysfunction in mice with cancer. The data suggests that these neutrophils are promising targets for future therapies to treat kidney injury in cancer patients.

Neutrophils play an important role in our immune system to protect us against infections. However, a tumour can trick neutrophils to become activated even in the absence of an infection, and as a consequence they contribute to disease progression and tissue damage.

"We have previously demonstrated that neutrophils form so called neutrophil extracellular traps, NETs, in the vasculature of mice with cancer, which cause impaired blood flow and inflammation in organs such as kidneys. Our new findings show that this leads to decreased kidney function in mice with cancer," says Anna-Karin Olsson, researcher at the Department of Medical Biochemistry and Microbiology at Uppsala University, who led the study.

The signs of kidney damage in mice resemble those observed in cancer patients, suggesting that NETs could be a cause of kidney dysfunction also in humans.

The study also shows that kidney function can be restored in mice with cancer through treatment, using an inhibitor to target the enzyme peptidyl arginine deiminase 4 (PAD4) - an enzyme required for neutrophils to form NETs. This is promising since it shows that kidney function can be restored if NETs are removed. The inhibitor (GSK484) has previously proven to be effective in preventing formation of NETs both in mouse and human neutrophils in test tubes. This study is the first to demonstrate the potential of the inhibitor GSK484 to prevent kidney damage in mice with cancer.

"We believe that these findings can lead to novel treatment options to prevent kidney damage and improve survival rates in cancer patients," says Jessica Cedervall, researcher at the Department of Medical Biochemistry and Microbiology at Uppsala University.
-end-


Uppsala University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.